baber/WOPTO huggingface dataset:
Patent WO-2023106987-A1 (WO)
Inventor: NILSSON CURT OVE
IPC: F16K1/226
Filed: 2022-12-02
Abstract: La présente invention se rapporte à une vanne papillon comprenant un logement de vanne (2, 3) ayant un passage (4) pour un milieu fluide ; un siège de vanne sous la forme d'une bague de siège (8) pouvant être déplacé dans une direction radiale, par rapport à l'axe dudit passage (4), dans une fente (7) dans ledit logement de vanne (2, 3) ; une vanne d'étranglement (5) agencée de sorte à pouvoir pivoter autour d'un axe de rotation (23) au moyen d'une tige (6) entre une position ouverte et une position d'arrêt, ladite vanne d'étranglement (5) présentant une face d'étanchéité (21) sur la périphérie (18) qui est pressée contre ladite bague de siège (8) lorsque ladite vanne d'étranglement (5) est dans ladite position d'arrêt ; une pluralité de cercles ronds (Dn) formant ladite périphérie (18) et un plus grand cercle rond (De) de ladite périphérie (18) étant positionné dans un plan (Pe) parallèle au plan de base (P0) et le plus proche de celui-ci comprenant ledit axe de rotation (23) et ayant un point central (Ce) définissant une ligne centrale (22) de la vanne d'étranglement (5) positionnée au centre par rapport audit plus grand cercle rond (De), lesdits plans (P0, Pe) s'étendant perpendiculairement à ladite ligne centrale (22) et un point central (Cs) du plus petit cercle rond (Ds) de ladite périphérie (18) étant positionné dans un plan inférieur (Ps) parallèle auxdits plans (P0, Pe) et ayant un point central (Cs) qui, dans un plan de symétrie (PP) comprenant ladite ligne centrale (22) est positionné le long de ladite ligne centrale (22) et dans un plan perpendiculaire (PS) audit plan de symétrie (PP), comprenant ladite ligne centrale (22) ayant ledit point central (Cs) positionné à l'écart d'une distance (Xs) depuis ladite ligne centrale (22) de la vanne d'étranglement (5), ladite face d'étanchéité (21) ayant une forme sphérique incurvée.
Patent SG-46380-A1 (SG)
Title: New xanthine derivatives with adenosine- antagonistic activity
Inventor: KUFNER-MUHL ULRIKE
IPC: C07H19/04
Filed: 1989-12-19
Abstract: Xanthines of formula (I) and their optical isomers and acid-addn. salts are new: R1 = 1-6C alkyl, 3-4C alkenyl or 3-4C alkynyl; R2 = 1-6C alkyl, 3-4C alkenyl, 3-4C alkynyl or opt. substd. benzyl; R3 = (a) C-bonded satd. or unsatd. 5- to 7-membered heterocyclyl contg. one or more O and/or S atoms, opt. substd. by 1-6C alkyl, oxo, CHO, CH2OR4, CH2OR7, COOR4 or CONR5R6; where furyl and thienyl gps. are opt. also substd. and tetrahydrofuryl gps. are opt. also substd; (b) 4-8C cycloalkenyl opt. substd. by 2-4C alkenyl; (c) a 4-8C cycloalkanone or cycloalkanol gp. opt. alpha-substd. by 2-6C alkenyl, 2-6C alkynyl, opt. substd. benzyl, CH2OR4, CH2COOR7 or CH2CH2CN; (d) 3-8C cycloalkyl opt. substd. by 1-6C alkyl, =CH2, =NNHAr, =NNHR, =NOH, OCONHAr, OCONHR, OR4, OR7, (CH2)xCOOR4, (CH2)xNR4R4, (CH2)xCONR5R6, (CH2)xOR4, (CH2)xOR7 or =CHA; (e) 3-8C cycloalkyl gem-substd. by OH and 1-6C alkyl, vinyl, allyl or opt. substd. phenyl or (1-4C alkyl)phenyl; (f) 3-8C cycloalkyl gem-substd. by ORa and ORb, or (g) 3,4-methylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 2-fluorenyl, 9-fluorenyl or a bicyclic gp., e.g. of formula (i)-(iii). Ar = opt. substd. aryl; R = 1-6C alkyl, x = 0-4; A = COOR4, CN, CONR5,R6, CH=CHCOOR4, CH=CHCONR5R6, CH2OR4 or CH2OR7; Ra and Rb = 1-4C alkyl, or Ra+Rb = 2-3C alkylene opt. substd. by 1 or 2 of 1-5C alkyl, 2-6C alkoxycarbonyl and 1-5C hydroxyalkyl; R4 = H, 1-13C alkyl, 3-13C alkenyl, propargyl, trityl or opt. substd. 3-6C cycloalkyl or benzyl; R5 = H, 1-6C alkyl or opt. substd. 3-6C cycloalkyl; R6 = H, 1-6C alkyl, opt. substd. benzyl, (CH2)nNR5R5, ((CH2)nO(CH2)mO)k(CH2)nNR5R5, (CH2)nQ(CH2)nNR5R5, or C-bonded piperidinyl opt. substd. ; or NR5R6 is a 5- to 7-membered ring opt. contg. another heteroatom and opt. substd. ; n = 2-8; m = 2-6; k = 0 or 1; Q = piperazine-1,4-diyl opt. substd. ; R7 = acyl derived from a natural amino acid, 2-14C alkanoyl, methyloxyacetyl, camphanoyl, abietoyl, 4-aminobutyryl, opt. substd. benzoyl or COB1; B1 = opt. substd.
Patent SG-143011-A1 (SG)
Title: Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Inventor: BEUME ROLF
IPC: A61K31/167
Filed: 1994-07-02
Abstract: Fluoralkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors Compounds of formula (I), in which one of the substituents R1 or R2 stands for hydrogen, 1-6C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, benzyloxy or totally or partially fluorine-substituted 1-4C-alkoxy, and the other stands for totally or partially fluorine-substituted 1-4C-alkoxy, and R3 stands for phenyl, pyridyl, R31, R32 and R33-substituted phenyl or R34, R35, R36 and R37-substituted pyridyl, in which R31 stands for hydroxy, halogen, cyano, carboxyl, trifluoromethyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C- alkoxycarbonyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, amino, mono- or di-1-4C-alkylamino or 1-4C-alkylcarbonylamino; R32 stands for hydrogen, hydroxy, halogen, amino, trifluoromethyl, 1-4C-alkyl or 1-4C-alkoxy; R33 stands for hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy; R34 stands for hydroxy, halogen, cyano, carboxyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl or amino; R35 stands for hydrogen, halogen, amino or 1-4C-alkyl; R36 stands for hydrogen or halogen; and R37 stands for hydrogen or halogen. These compounds constitute new effective bronchotherapeutic drugs.
Patent SG-85069-A1 (SG)
Title: An electric traction motor vehicle
Inventor: RENE JEANNERET
IPC: B60L50/10
Filed: 1994-05-24
Abstract: PCT No. PCT/IB94/00119 Sec. 371 Date Mar. 21, 1995 Sec. 102(e) Date Mar. 21, 1995 PCT Filed May 24, 1994 PCT Pub. No. WO94/27837 PCT Pub. Date Dec. 8, 1994The vehicle (1) comprises a driving wheel (2) driven by an electric motor (3) whose control circuit (4) is supplied by a generator (6) coupled to a fuel engine (5), and a sensor (18) supplying a power-setting control signal (SC) representative of the position of an accelerator pedal (17) and hence of the desired power that the electric motor (3) has to supply to the wheel (2). To avoid having to provide the vehicle (1) with a large capacity traction battery, the vehicle further comprises means (7, 14 to 16, 19, 20) responsive to the power setting signal (SC) to regulate the rotational speed of the fuel engine (5) to the value at which the latter supplies a mechanical power (Pm) that is equal, firstly, to the desired power and, secondly, to a predetermined fraction of its maximum power.
Patent WO-2005031596-A1 (WO)
Title: Method for transforming a digital signal from the time domain into the frequency domain and vice versa
Inventor: HUANG HAIBIN
IPC: G06F17/14
Filed: 2004-05-06
Abstract: A method for transforming a digital signal from the time domain into the frequency domain and vice versa using a transformation function comprising a transformation matrix, the digital signal comprising data symbols which are grouped into a plurality of blocks, each block comprising a predefined number of the data symbols. The method includes the process of transforming two blocks of the digital signal by one transforming element, wherein the transforming element corresponds to a block-diagonal matrix comprising two sub­ matrices, wherein each sub-matrix comprises the transformation matrix and the transforming element comprises a plurality of lifting stages and wherein each lifting stage comprises the processing of blocks of the digital signal by an auxiliary transformation and by a rounding unit.
Patent SG-148034-A1 (SG)
Title: Non-neurotoxic plasminogen activating factors for treating stroke
Inventor: SOEHNGEN MARIOLA
IPC: A61K38/49
Filed: 2002-10-31
Abstract: NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to provide a new therapeutic concept for treating stroke in humans.
Patent SG-144001-A1 (SG)
Title: An operator training apparatus for a manufacturing environment and a method of use thereof
Inventor: TANAKA MIHOKO
IPC: G06Q50/00
Filed: 2006-12-29
Abstract: AN OPERATOR TRAINING APPARATUS FOR A MANUFACTURING ENVIRONMENT AND A METHOD OF USE THEREOF The present invention relates to an operator training apparatus for a manufacturing environment including an instructor tool kit for the use of a trainer, said instructor tool kit further including a monitor module; an evaluation module and a central controller, a plant simulation model to enact the plant simulation for the manufacturing environment, one operator console for the use of a trainee and a storage device to store a response of a trainer and/ or a trainee.Further, the invention provides a method of training using a training simulator including loading and running the simulation program, conducting a trainer simulation, demonstrating a proper recovery measure according to the simulation, generating a response indicator in response to the simulation, storing the response indicator to a storage device, starting the simulation for one trainee, retrieving and displaying the trainer's response and comparing with the trainee's response when the simulation is in session.
Patent SG-142252-A1 (SG)
Title: Heat dissipation apparatus utilizing empty component slot
Inventor: HOSS SHAWN P
Filed: 2007-10-11
Abstract: HEAT DISSIPATION APPARATUS UTILIZING EMPTY COMPONENT SLOT A heat dissipation apparatus includes a heat transfer base that is operable to couple to a heat producing component that is operable to couple to a first component connector and be located in a first component slot defined by the first component connector, wherein the first component connector is located adjacent to and spaced apart from a second component connector that defines a second component slot. A heat dissipating member extends from the heat transfer base such that the heat dissipating member is located in the second component slot that is defined by the second component connector when the heat producing component is coupled to the first component connector and located in the first component slot. The heat dissipation apparatus may be coupled to a heat producing component and used to dissipate heat from the heat producing component when there are empty component connector slots located adjacent the component connector that the heat producing component is coupled to. Fig. 3a
Patent SG-148940-A1 (SG)
Title: Gaming machine and gaming method thereof
Inventor: SAITO HIROKI
IPC: A63F5/04
Filed: 2008-06-03
Abstract: GAMING MACHINE AND GAMING METHOD THEREOF A gaming environment is described. If a predetermined condition is met, one of plural games is selected as a free game. Here, realizable winning combination and reel are different in each of selectable plural games. If the game is selected, symbols are variably displayed and stopped displayed using the reel corresponding to the selected game. And, if the combination of stopped displayed symbols is any of the winning combination corresponding to the selected game, the payout number corresponding to the realized winning combination is provided to a player. Figures 1A and 1B
Patent SG-157359-A1 (SG)
Title: Electro-active intraocular lenses
Inventor: BLUM RONALD D
Filed: 2005-10-31
Abstract: An intraocular lens system is presented that comprises an electro-active lens comprising multiple independently controllable zones or pixels, and a controller capable of being remotely programmed.
Patent SG-161204-A1 (SG)
Title: Chair providing enhanced health care and comfort
Inventor: SARKAR MANJU
IPC: B60N2/90
Filed: 2010-03-12
Abstract: Chair for enhancing comfort when required to be seated for long durations, such as in aeroplane, auditorium, theater, waiting lounge, :automobile, library and the like. When for use in a public seating arrangement having multiple chairs laid one behind the other, a foot rest (210) is provided on the chair, at a height H from the floor level (220), the foot rest (210) on a first chair (100a) being usable by a person seated on asecond chair (100b) that is behind the first chair (100a). In another aspect, the foot rest (210) is provided at a front side (290) of the chair at a height H that is closer to a seat level (280) than to the floor level (220), for use by a person seated on the same chair, while having to lift the knee joints significantly above the seat level (280). The Most Illustrative Drawing: Figure 2a
Patent SG-175667-A1 (SG)
Title: Integrated circuit package system with leadframe substrate
Inventor: CHEONHEE LEE
Filed: 2005-11-14
Abstract: INTEGRATED CIRCUIT PACKAGE SYSTEM WITH LEADFRAME SUBSTRATEAn integrated circuit package system is provided. A dual-type leadframe having first and second rows of leads is formed. A first row of bumps is formed on an integrated circuit chip. Solder paste is placed on the first row of leads, and the first row of bumps is pressed into the solder paste on the first row of leads. The solder paste is reflow soldered to form solder and connect the integrated circuit chip to the first row of leads, and the integrated circuit chip, the first row of bumps, the solder, and the leadframe are encapsulated.(Fig. 1 )
Patent SG-176260-A1 (SG)
Title: Processes for the preparation of substituted tetrahydro beta-carbolines
Inventor: HWANG PETER SEONGWOO
Filed: 2010-05-27
Abstract: Provided herein are improved processes for the synthesis of substituted tetrahydro beta-carboline derivatives. In particular, provided herein are improved processes useful for the preparation of (S)-4-chlorophenyl 6-chloro- 1 -(4-methoxyphenyl)-3,4-dihydro- 1 H-pyrido [3,4-b]indole-2(9H)-carboxylate. Formula (I)
Patent SG-176939-A1 (SG)
Title: Method for treatment of diseases
Inventor: BAR-OR DAVID
Filed: 2010-06-22
Abstract: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular- hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.
Patent WO-2013043132-A1 (WO)
Title: Patient stratification and determining clinical outcome for cancer patients
Inventor: THIERY JEAN PAUL
IPC: G16B20/00
Filed: 2012-09-24
Abstract: In a first aspect the present invention is directed to a method of generating a scheme allowing classification of a cancer of an individual patient for estimating a clinical outcome for said patient. It also refers to a method of estimating a clinical outcome of a patient suffering from epithelial ovarian cancer (EOC). The present invention also refers to a method of determining whether the epithelial mesenchymal score of a patient suffering from a cancer can be changed by administering an EMT reversal agent to increase patients susceptibility for an anti-cancer treatment.
Patent SG-183636-A1 (SG)
Title: Energizing a coil of a solenoid of a directional control valve
Inventor: DAVIS JULIAN R
Filed: 2012-02-17
Abstract: A method of energizing a coil of a solenoid of a directional control valve (1), comprises energizing the coil with a voltage, controlling said voltage and detecting the current in the coil at which an armature of the solenoid moves between a first position in which the solenoid is operated to a second position in which the solenoid is not operated and using that current increased by a margin as an operating current for energizing the coil of the solenoid.Figure lb
Patent SG-181125-A1 (SG)
Title: Nanoparticle composition and methods of making the same
Inventor: ZINN ALFRED A
IPC: C01B32/50
Filed: 2010-06-17
Abstract: A method of fabricating copper nanoparticles includes heating a copper salt solution that includes a copper salt, an N,N'-dialkylethylenediamine, and a C6-C18 alkylamine in an organic solvent to a temperature between about 30°C to about 50°C; heating a reducing agent solution that includes a reducing agent, an N,N'-dialkylethylenediamine, and a C6-C18 alkylamine in an organic solvent to a temperature between about 30°C to about 50°C; and adding the heated copper salt solution to the heated reducing agent solution, thereby producing copper nanoparticles. A composition includes copper nanoparticles, a C6-C18 alkylamine and an N,N'-dialkylethylenediamine ligand. Such copper nanoparticles in this composition have a fusion temperature between about 100°C to about 200°C. A surfactant system for the stabilizing copper nanoparticles includes an N,N'-dialkylethylenediamine and a C6-C18 alkylamine.
Patent SG-183344-A1 (SG)
Title: Method for producing 1-amino-1-alkoxycarbonyl-2-vinylcyclopropane
Inventor: ASUMA YUUKI
Filed: 2011-02-16
Abstract: Provided is a novel method for producing (1R,2S)/(1S,2R)-1-amino-1-alkoxycarbonyl-2-vinylcyclopropane which is useful as an intermediate for synthesizing a therapeutic agent for hepatitis C, and also provided is a novel method for producing an intermediate for synthesizing (1R,2S)/(1S,2R)-1-amino-1-alkoxycarbonyl-2-vinylcyclopropane. According to the methods, when a trans-2-butene derivative having a leaving group at each of the 1- and 4-positions is reacted with a malonic acid ester in the presence of a base, a specific amount of an alkali metal alkoxide or an alkali metal hydride is used as the base, and further a specific amount of a malonic acid ester is used to produce a cyclopropane diester, and further, chiral or achiral 1-amino-1-alkoxycarbonyl-2-vinylcyclopropane and a salt thereof are synthesized using the cyclopropane diester.
Patent SG-183877-A1 (SG)
Title: Method and apparatus in a pneumatic material conveying system, and a waste conveying system
Inventor: SUNDHOLM GOERAN
Filed: 2011-03-03
Abstract: Method in a pneumatic material conveying system, such as in a waste conveying system, which conveying system comprises at least one input point (61) of material, more particularly of waste material, a material conveying pipe (100), which can be connected to an input point (61), and a separating device, in which the material to be transferred is separated from the conveying air, and also means for achieving a pressure difference and/or a conveying air flow in the conveying pipe (100) at least during the transfer of material. In the method material is conveyed from an input point (61) to the separating means (106) or an accumulator tank of a subsystem (1), where the material is separated from the conveying air, and in a second phase the separating means (106) or the accumulator tank of the subsystem (1) is emptied.
Patent SG-185128-A1 (SG)
Title: Monitoring health and disease status using clonotype profiles
Inventor: FAHAM MALEK
Filed: 2011-05-04
Abstract: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.
Patent SG-192273-A1 (SG)
Title: Method for producing phenoxypyridine derivative
Inventor: TAKAHASHI MASABUMI
Filed: 2012-03-27
Abstract: Disclosed is a method for producing a compound represented by formula (I), or a salt thereof, the method being characterized in that a compound represented by formula (II), or a salt thereof, is reacted with an aniline derivative represented by formula (III), in water or in a mixed solvent of water and an organic solvent, in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and substantially in the absence of a base. (In the formulas, R1 is a 4-[3-(dimethylamino)azetidin-1-yl]piperidin-1-yl group, a 4-(4-methylpiperazin-1-yl)piperidin-1-yl group, a 3-hydroxyazetidin-1-yl group, or a methyl(1-methylpiperidin-4-yl)amino group; R2, R3, R4, and R5 are each identical or different and signify a hydrogen atom or a fluorine atom; and R6 signifies a hydrogen atom or a halogen atom.)
Patent WO-2015142280-A1 (WO)
Inventor: DECRAENE JAMES CHRISTIAN
IPC: G16B45/00
Filed: 2014-03-18
Abstract: A system for generating a user activity grid table is provided. The system includes processes for retrieving raw data from a server and processing this data to generate a user activity grid table that displays the timings that a user or a plurality of users spends in a particular geographical location, at a particular website or watching a particular channel.
Patent WO-2016133459-A1 (WO)
Title: Représentation et dissémination de préférences d'utilisateur
Inventor: YEN PHILIP WEIPING
IPC: G06Q30/02
Filed: 2016-02-10
Abstract: L'invention concerne un procédé servant à disséminer des données de préférence utilisateur, le procédé comprenant les étapes consistant : à déterminer une représentation de préférences d'utilisateur, la représentation de préférence d'utilisateur étant configurée pour représenter des données de préférence d'utilisateur d'un utilisateur vers n'importe quels promotions, achats et paiement ; et à disséminer la représentation de préférence d'utilisateur à une pluralité de destinataires, la pluralité de destinataires traitant la représentation de préférence d'utilisateur (10) pour récupérer les données des préférences de l'utilisateur de l'utilisateur, pour réguler la fourniture de contenu à l'utilisateur.
Patent WO-2018044239-A1 (WO)
Title: Procédé de traitement du cancer par des oligonucléotides antisens ciblant prdm15
Inventor: GUCCIONE ERNESTO
IPC: G01N33/68
Filed: 2017-09-04
Abstract: La présente invention concerne des oligonucléotides antisens pour moduler l'activité de PRDM15 et leur utilisation dans le traitement du cancer. En particulier, lesdits oligonucléotides antisens sont capables d'induire le saut d'un exon d'un ARNm de PRDM15. La présente invention concerne également un procédé pour déterminer un pronostic chez un patient atteint d'un cancer, ou sélectionner une stratégie thérapeutique pour un patient atteint d'un cancer, par évaluation du niveau d'acide nucléique, de protéine ou d'activité de PRDM15 dans un échantillon.